PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas
- PMID: 2406025
- DOI: 10.1016/0092-8674(90)90659-3
PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas
Abstract
We recently detected a novel activated oncogene by transfection analysis on NIH 3T3 cells in five out of 20 primary human thyroid papillary carcinomas and in the available lymph node metastases. We designated this transforming gene PTC (for papillary thyroid carcinoma). Here we describe the molecular cloning and sequencing of the gene. The new oncogene resulted from the rearrangement of an unknown amino-terminal sequence to the tyrosine kinase domain of the ret proto-oncogene. This gene rearrangement was detected in all of the transfectants and in all of the original tumor DNAs, but not in normal DNA of the same patients, thus indicating that this genetic lesion occurred in vivo and is specific to somatic tumors. Moreover, the transcript coded for by the fused gene was detected in an additional PTC-positive human papillary carcinoma for which mRNA was available.
Similar articles
-
Molecular characterization of RET/PTC3; a novel rearranged version of the RETproto-oncogene in a human thyroid papillary carcinoma.Oncogene. 1994 Feb;9(2):509-16. Oncogene. 1994. PMID: 8290261
-
Lack of PTC gene (ret proto-oncogene rearrangement) in human thyroid tumors.Endocrinol Jpn. 1991 Dec;38(6):627-32. doi: 10.1507/endocrj1954.38.627. Endocrinol Jpn. 1991. PMID: 1823030
-
Ret oncogene activation in human thyroid neoplasms is restricted to the papillary cancer subtype.J Clin Invest. 1992 May;89(5):1517-22. doi: 10.1172/JCI115743. J Clin Invest. 1992. PMID: 1569189 Free PMC article.
-
[Rearrangement of the RET gene in papillary thyroid carcinoma].Wiad Lek. 2001;54 Suppl 1:64-71. Wiad Lek. 2001. PMID: 12182064 Review. Polish.
-
The RET proto-oncogene in medullary and papillary thyroid carcinoma. Molecular features, pathophysiology and clinical implications.Virchows Arch. 1997 Jul;431(1):1-9. doi: 10.1007/s004280050062. Virchows Arch. 1997. PMID: 9247627 Review.
Cited by
-
RET gene fusion and emergent Selpercatinib resistance in a calcitonin-rich neuroendocrine carcinoma: a case report.Front Oncol. 2024 Feb 14;14:1360492. doi: 10.3389/fonc.2024.1360492. eCollection 2024. Front Oncol. 2024. PMID: 38469239 Free PMC article.
-
Selpercatinib combination with the mitochondria-targeted antioxidant MitoQ effectively suppresses RET-mutant thyroid cancer.NPJ Precis Oncol. 2024 Feb 20;8(1):39. doi: 10.1038/s41698-024-00536-7. NPJ Precis Oncol. 2024. PMID: 38378752 Free PMC article.
-
RET fusion genes in pediatric and adult thyroid carcinomas: cohort characteristics and prognosis.Endocr Relat Cancer. 2023 Oct 26;30(12):e230117. doi: 10.1530/ERC-23-0117. Print 2023 Dec 1. Endocr Relat Cancer. 2023. PMID: 37882481 Free PMC article.
-
Progress in Thyroid Cancer Genomics: A 40-Year Journey.Thyroid. 2023 Nov;33(11):1271-1286. doi: 10.1089/thy.2023.0045. Epub 2023 Sep 4. Thyroid. 2023. PMID: 37668657 Review.
-
Fusion Oncogenes in Patients With Locally Advanced or Distant Metastatic Differentiated Thyroid Cancer.J Clin Endocrinol Metab. 2024 Jan 18;109(2):505-515. doi: 10.1210/clinem/dgad500. J Clin Endocrinol Metab. 2024. PMID: 37622214 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
- Actions
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
